905725-45-3

Upstream product

• 1021935-30-7 C₈H₁₁N*C₁₃H₁₆O₃ 
• 905725-46-4 C₈H₁₁N*C₁₃H₁₆O₃ 

Downstream Products

• 905724-71-2 ethyl [(1S)-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]acetate 
• 905725-46-4 C₈H₁₁N*C₁₃H₁₆O₃ 

Relevant academic research and scientific papers

ANTIDIABETIC BICYCLIC COMPOUNDS

Biaryl ethers in which one of the aromatic πngs is fused to a cycloalkyl or heterocyclic πng, which is attached to a thiazohdinedione or oxazohdmedione πng, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes melhtus, and of conditions that often occur with type 2 diabetes, including insulin resistance, obesity, and lipid disorders.

ANTIDIABETIC BICYCLIC COMPOUNDS

Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that often accompany this disease, including insulin resistance, obesity and lipid disorders.

ANTIDIABETIC BICYCLIC COMPOUNDS

Bicyclic compounds containing a phenyl or pyridyl ring fused to a cycloalkyl or heterocyclic ring, to which is attached a 5-membered heterocyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.